Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort
| dc.rights.license | open | en_US |
| dc.contributor.author | ROUYER, M. | |
| dc.contributor.author | OUDARD, S. | |
| dc.contributor.author | JOLY, F. | |
| dc.contributor.author | FIZAZI, K. | |
| dc.contributor.author | TUBACH, F. | |
| dc.contributor.author | JOVE, J. | |
| dc.contributor.author | LACUEILLE, C. | |
| dc.contributor.author | LAMARQUE, S. | |
| dc.contributor.author | GUIARD, E. | |
| dc.contributor.author | BALESTRA, A. | |
| dc.contributor.author | DROZ-PERROTEAU, C. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | FOURRIER-REGLAT, Annie | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MOORE, Nicholas | |
| dc.date.accessioned | 2020-07-10T14:54:11Z | |
| dc.date.available | 2020-07-10T14:54:11Z | |
| dc.date.issued | 2019-12 | |
| dc.identifier.issn | 1532-1827 (Electronic) 0007-0920 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/10416 | |
| dc.description.abstractEn | BACKGROUND: Cabazitaxel is a treatment of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel failure. The FUJI cohort aimed to confirm the real-life overall and progression-free survival (OS, PFS) and safety of cabazitaxel. METHODS: Multicentre, non-interventional cohort of French mCRPC patients initiating cabazitaxel between 2013 and 2015, followed 18 months. RESULTS: Four hundred one patients were recruited in 42 centres. At inclusion, median age was 70, main metastatic sites were bones (87%), lymph nodes (42%) and visceral (20%). 18% had cabazitaxel in 2nd-line treatment, 39% in 3rd-line and 43% in 4th-line or beyond. All had prior docetaxel, and 82% prior abiraterone, enzalutamide or both. Median duration of cabazitaxel treatment was 3.4 months. Median OS from cabazitaxel initiation was 11.9 months [95% CI: 10.1-12.9]. In multivariate analyses, grade >/= 3 adverse events, visceral metastases, polymedication, and >5 bone metastases were associated with a shorter OS. Main grade >/= 3 adverse events were haematological with 8% febrile neutropenia. CONCLUSION: Real-life survival with cabazitaxel in FUJI was shorter than in TROPIC (pivotal trial, median OS 15.1 months) or PROSELICA (clinical trial 20 vs 25 mg/m(2), median OS, respectively, 13.4 and 14.5 months). There was no effect of treatment-line on survival. No unexpected adverse concerns were identified. STUDY REGISTRATION: It was registered with the European Medicines Agency EUPASS registry, available at www.encepp.eu, as EUPAS10391. It has been approved as an ENCEPP SEAL study. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | |
| dc.rights.uri | https://creativecommons.org/licenses/by/3.0/us/ | |
| dc.subject.en | PharmacoEpi-Drugs | |
| dc.title.en | Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | |
| dc.title.alternative | Br J Cancer | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1038/s41416-019-0611-6 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 31719685 | en_US |
| bordeaux.journal | British Journal of Cancer | en_US |
| bordeaux.page | 1001-1008 | en_US |
| bordeaux.volume | 121 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 12 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-02896685 | |
| hal.version | 1 | |
| hal.date.transferred | 2020-07-10T14:54:16Z | |
| hal.export | true | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=British%20Journal%20of%20Cancer&rft.date=2019-12&rft.volume=121&rft.issue=12&rft.spage=1001-1008&rft.epage=1001-1008&rft.eissn=1532-1827%20(Electronic)%200007-0920%20(Linking)&rft.issn=1532-1827%20(Electronic)%200007-0920%20(Linking)&rft.au=ROUYER,%20M.&OUDARD,%20S.&JOLY,%20F.&FIZAZI,%20K.&TUBACH,%20F.&rft.genre=article |
